In reply
We read with interest the letter from Gazulla et al in which they treated a 34-year-old man with AT with a combination of pregabalin (225 mg/d) and tiagabine (7.5 mg/d). The authors reported that pregabalin treatment improved the patient's gait (ie, he could walk more than 10 m without support) and that the addition of tiagabine increased the distance of unsupported walking to more than 20 m and facilitated execution of half turns. The improvements were sustained for an unspecified period after which the beneficial effects of the drugs disappeared and the drugs were withdrawn. Based on their observations, Gazulla et al proposed using pregabalin and tiagabine together rather than betamethasone to treat children with AT in whom we first raised several concerns about adverse effects.1